Sino Biopharma hits near 3-month peak on drug's clinical trial approval

Sino Biopharmaceutical

03/11/2023 07:51

** Shares of Sino Biopharmaceutical Ltd  1177.HK  jump 9.1%
to HK$3.37, their highest since Aug. 7, making it the biggest
pct gainer in Hang Seng Index  .HSI  
    ** Stock on course to end week up 15.4%, the best since
December 2020; 
    ** Co says China's National Medical Products Administration
has approved its developed TQG3902 "Angiotensin II" injection to
commence clinical trials for increasing blood pressure in adults
with septic shock or other distributive shock
    ** Says TQG3902 is the first angiotensin II injection in
China to receive investigational new drug approval
    ** Hong Kong's healthcare index  .HSCIH  rises 2.1%, Hang
Seng Index  .HSI  up 2.5%
    ** Stock down 26.5% YTD 

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))